RMIT-developed wearable heart monitor enters clinical trial

85
Lubdub's wearable ECG patch being used in the clinical trial. Image credit: RMIT

A wearable heart monitor developed from research at RMIT University is entering clinical trials in Perth, with the technology being tested for its ability to provide continuous cardiac monitoring outside hospital settings.

According to RMIT, the lightweight, gel-free and waterproof wireless patch, developed by Australian start-up Lubdub, tracks heart rhythms for up to 14 days and aims to provide data comparable to that collected by medical-grade electrocardiogram (ECG) Holter monitors.

The clinical trial begins this week at Midlands Medical Specialists in Perth, Western Australia, where patients prescribed Holter monitoring will wear the prototype device as part of the study.

Designed to be worn during everyday activities, the patch uses flexible sensors to maintain contact with the skin. Earlier testing involving healthy volunteers found the device comfortable to wear and produced promising results, according to RMIT.

RMIT Professor and Lubdub co-founder Sharath Sriram said the data collected by the patch was 18 times cleaner than that from traditional Holter monitors.

“The flexible sensors make better contact with the skin than those used in traditional Holter monitors,” he said.

Sriram said the technology could also reduce the workload involved in preparing cardiac reports, potentially allowing the same workforce to monitor up to 85 per cent more patients before the introduction of additional tools such as artificial intelligence.

The clinical trial will gather further evidence to support the technology’s development and potential regulatory approval.

Lubdub aims to integrate the ECG patch with non-invasive cardiac biomarker testing and wearable ultrasound imaging into a single software platform. RMIT has licensed the intellectual property for its ECG and biomarker inventions to the company.

Sriram said the technology could help improve access to cardiac monitoring, particularly in rural and remote communities, where access to specialist healthcare can be limited.

“Despite the high prevalence of cardiovascular disease – responsible for a third of deaths globally and nearly a quarter in Australia – early symptoms are often missed,” he said.

Lubdub was selected by the Heart Foundation as one of its 10 most promising heart health projects for 2026. In September, the company also secured an oversubscribed $6 million seed funding round, exceeding its original $3 million target.

RMIT Deputy Vice-Chancellor Research and Innovation Distinguished Professor Calum Drummond AO said the partnership demonstrated how university research could be translated into commercial products.

“Lubdub is focused on making a real difference to heart health through cutting-edge electronics invented right here at RMIT,” he said.

RMIT will continue working with Lubdub through research partnerships and access to pilot manufacturing facilities as the company progresses testing and development towards regulatory approval.